Angiotensin receptor blockers: Are they related to lung cancer?

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1669-1675

  Rao, Gowtham Adamane ^a   Mann, Joshua R ^b   Shoaibi, Azza ^c   Pai, Sachin G ^d   Bottai, Matteo ^e   Sutton, Shawn Scott ^f   Haddock, Kathlyn Sue ^a   Bennett, Charles Lee ^f   Hebert, James R ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Louisiana State University Health Sciences Center at Shreveport   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

angiotensin receptor blockers; cancer registry; Department of Veterans Affairs; drug safety; inverse probability of treatment weight; lung cancer; propensity score; survival analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; OLMESARTAN; STEROID 5ALPHA REDUCTASE INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; SURVIVAL;

EID: 84880570523     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283621ea3     Document Type: Article

References (16)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11:627-636.
2. FDA Drug Safety Communication: no increase in risk of cancer with certain blood pressure drugs -angiotensin receptor blockers (ARBs). www.fda.gov [Accessed 31 May 2012].
3. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network metaanalyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65-82.
4. Collaboration TAT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011; 29:623-635.
5. Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123:1729-1736.
6. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012; 344:e2697.
7. Opelz G, Dohler B. Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report. Am J Trans 2011; 11:2483-2489.
8. McGinnis KA, Brandt CA, Skanderson M, Justice AC, Shahrir S, Butt AA, et al. Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source. Nicotine Tobacco Res 2011; 13:1233-1239.
9. Department of Veterans Affiars (VA). VA Information Resource Center (VIReC) web site. www.virec.research.va.gov [Accessed 2 March 2012].
10. Hernan MA. A definition of causal effect for epidemiological research. J Epidemiol Community Health 2004; 58:265-271.
11. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60:578-586.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998; 17:2265-2281.
13. Kurth T, Walker AM, Glynn RJ, Chan AK, Gaziano JM, Berger K, Robins JM. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163:262-270.
14. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005; 61:962-973.
15. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 2011; 107:1028-1033.
16. Messerli FH, Bangalore S, Torp-Pedersen C, Staessen JA, Kostis JB. Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. Eur Heart J 2013; 34:1095-1098. Center) Network